Lytix Biopharma
P.O. Box 6447
Tromso Research Park
Tromso
N-9294
Website: http://www.lytixbiopharma.com/
Email: post@lytixbiopharma.com
42 articles about Lytix Biopharma
-
Lytix Biopharma to present at the 'Frontiers in Cancer Immunotherapy 2023', invited by New York Academy of Sciences
5/3/2023
Lytix Biopharma AS is pleased to announce that Dr Øystein Rekdal, CEO in Lytix Biopharma, will give an oral presentation at the `Frontiers in Cancer Immunotherapy 2023' conference, which is taking place in New York, USA.
-
Lytix Biopharma appoints new Chairman of the Board
4/19/2023
Lytix Biopharma AS, a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at 's General Assembly.
-
Lytix Biopharma appoints new Chairman of the Board - April 19, 2023
4/19/2023
Lytix Biopharma AS, a clinical stage immuno-oncology company, announces the election of a new Chairman of the Board at 's General Assembly.
-
Lytix Biopharma: Annual Report for 2022
3/30/2023
Lytix Biopharma AS announces that it has published its Annual Report for 2022, which was approved by the board of directors on March 29, 2023.
-
Lytix Biopharma presents fourth quarter and second half 2022 results
2/16/2023
Lytix Biopharma, a Norwegian immuno-oncology company, releases its fourth quarter and second half 2022 results - Steady progress towards improving cancer treatment outcomes.
-
Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February
2/9/2023
Lytix Biopharma AS, a Norwegian immuno-oncology company, will release its fourth quarter and second half 2022 results on Thursday, 16 February 2023 at 8am CEST.
-
Lytix Biopharma third quarter 2022 results
11/17/2022
Lytix Biopharma, a Norwegian immune-oncology company, releases its third quarter 2022 results.
-
Lytix Biopharma announces expansion of the ATLAS-IT-05 study to Europe
11/14/2022
Lytix Biopharma, a Norwegian immuno-oncology company, announces site activation for the ATLAS-IT-05 study in three European countries.
-
Lytix Biopharma presents compelling data in collaboration with research groups at National Cancer Institute and Weill Cornell Medicine, USA.
11/10/2022
Lytix Biopharma AS today announces the release of new data describing how LTX-315 treatment activates specific immune cells that are critical for a proper priming of tumor-specific T cells.
-
Lytix Biopharma will host Capital Markets Day - November 22, 2022
11/1/2022
Lytix Biopharma, is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, November 22, 2022.
-
Lytix Biopharma announces that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/5/2022
Lytix Biopharma today announces that an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022.
-
Lytix Biopharma announces approval to expand the ATLAS-IT-05 study to Europe
9/7/2022
Lytix Biopharma, a Norwegian immuno-oncology company, announces the regulatory approval from European authorities to commence the ATLAS-IT-05 study in three European countries.
-
Lytix Biopharma appoints Stephen Worsley as Chief Business Officer
9/5/2022
Lytix Biopharma, a Norwegian immune-oncology company, announces the appointment of Stephen Worsley as Chief Business Officer.
-
Lytix Biopharma: Second quarter and first half of 2022 results
8/25/2022
Lytix Biopharma, a Norwegian immune-oncology company, releases its second quarter and first half 2022 results - New encouraging clinical data.
-
Lytix Biopharma AS announces that LTX-315 with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with metastatic soft tissue sarcoma (STS).
6/5/2022
Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma.
-
Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022
5/27/2022
Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces that an abstract relating to LTX-315 in combination with Adoptive Cell Therapy has been selected for presentation at a Poster Session during American Society of Clinical Oncology 2022.
-
Lytix Biopharma - Invitation to Capital Markets Day in Oslo, June 1, 2022
5/19/2022
The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast.
-
Lytix Biopharma to host Capital Markets Day - June 1, 2022
5/3/2022
Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022
-
Lytix Biopharma to present at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022.
-
Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals Inc. triggered by first patient dosed with LTX-315
4/5/2022
Lytix Biopharma AS notes that the first patient has been dosed in Verrica Pharmaceuticals Inc.'s Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (skin cancer).